11/2/2026

speaker
Nikki
Conference Call Operator

Hello and welcome everyone joining today's Neurocrine Biosciences third quarter 2026 earnings call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star one on your telephone keypad. We ask that please limit yourself to one question. Please note this call is being recorded. and we are standing by if you should need any assistance. It is now a pleasure to turn the meeting over to Todd Tushla, Vice President of Investor Relations. Please go ahead.

speaker
Todd Tushla
Vice President, Investor Relations

Thank you and happy Monday wherever it is that you may be. Welcome to Neurocrine Biosciences third quarter 2026 earnings call. Joining me on today's call are Kyle Gano, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, Eiry Roberts, Chief Medical Officer, and Samir Sadanti, Chief Business Officer. During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. In addition, some of the information discussed today includes non-GAAP financial measures that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the investor relations page of the company's website. Following prepared remarks, we'll be happy to take your questions. With that, I'll hand the call off to Kyle.

speaker
Kyle Gano
Chief Executive Officer

Good afternoon, everyone. Nearly two years ago, on my first earnings call at CEO, I shared my optimism about Neurocrine's future and the significant opportunities ahead. Today, that confidence has only grown stronger as I remain deeply confident in our ability to drive sustained growth and create long-term value for our shareholders. Our strategy to build a leading biopharmaceutical company is grounded in execution and delivering meaningful results. In the third quarter, we generated record net product sales of more than $1.1 billion and record profitability. These results underscore the strength of our diversified portfolio of three first-in-class medicines and our growing ability to reach and serve more patients than ever before. This momentum positions us well to drive continued growth across Ingresa, Chronicity, and VipedXR in 2027 and beyond. The strength of our growing commercial business and financial position also enables us to continue investing in our industry-leading pipeline. With several important clinical milestones anticipated in 2027, including Phase III data readouts for Osevanpator and major depressive disorder, and direct bleeding and schizophrenia, we believe Neurocrine is approaching a potentially transformative period, one that could further expand our pipeline, strengthen our long-term growth prospects, and extend our impact on patients. Overall, Neurocrine's third quarter performance exemplifies the strength of our strategy, the discipline of our execution, and the significant opportunity it has to create long-term value. As we close out the year, we look forward to hosting our 2026 R&D Day in New York City on December 15th. The event will feature a BICADXR panel discussion with Dr. Jennifer Miller, Professor of Pediatric Endocrinology and Director of the Potter-Willie Syndrome Program at the University of Florida College of Medicine, as well as an update on our pipeline. I look forward to sharing our progress, engaging with the investment community, and discussing the opportunities ahead as we enter what promises to be a catalyst-rich 2027. With that, I'll turn the call over to Matt.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation